Delve Bio
Latest round
- Series A
Last raised
- Jan 2023
Total raised
- $36M
Investors
- 3
About Delve Bio
Based in California, US, and founded in 2022, Delve Bio Inc. enables single-shot, pathogen-neutral detection of neuro-infectious pathogens in cerebrospinal fluid (CSF). The company was founded by Brad Murray, who is leading the firm as CEO as of 2023. The company offers molecular insights for the precision care of patients by giving a single shot pathogen-unbiased, pathogen-agnostic detection of neuro-infectious pathogens in cerebrospinal fluid (CSF). It uses mNGS to give labs and physicians the information they need to diagnose both common and uncommon infectious disorders.
Who invested in Delve Bio
3 investors across 1 round
See all investors in Delve Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jan 3, 2023
Amount
$36M
Investors
Questions about Delve Bio
Who invested in Delve Bio?
Delve Bio has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Delve Bio raised?
Delve Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Delve Bio last raise money?
Delve Bio's most recent round on record is a Series A, in Jan 2023.
What does Delve Bio do?
Based in California, US, and founded in 2022, Delve Bio Inc.
Where is Delve Bio headquartered?
Delve Bio is headquartered in San Francisco, US.
Which VCs invest in companies like Delve Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Delve Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Delve Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.